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Background/aim: The aim of this study was to investigate the relationship between familial Mediterranean fever and female sexual
dysfunction and premenstrual syndrome.
Materials and methods: This study included 36 patients with familial Mediterranean fever and 33 healthy volunteers. Familial
Mediterranean fever was diagnosed according to the Tel Hashomer criteria and familial Mediterranean fever mutations were identified
in all of the patients. The patients and healthy volunteers were compared in terms of anxiety, depression, sexual dysfunction, and
premenstrual syndrome, and a model was created that describes the relationships among these variables.
Results: We found statistically significant differences between the groups in terms of anxiety, premenstrual syndrome, and Golombok
Rust Inventory of Sexual Satisfaction frequency and vaginismus subscale scores. There was no difference in depression scores between
the groups.
Conclusion: Familial Mediterranean fever is a rheumatic disease that predisposes patients to sexual dysfunction and premenstrual
syndrome, which emerges as direct and indirect psychological factors.
Key words: Familial Mediterranean fever, premenstrual syndrome, sexual dysfunction

1. Introduction
Familial Mediterranean fever (FMF) is an inherited
autoinflammatory disease. The prevalence of FMF in
Middle Eastern populations and other ethnic groups living
around the Mediterranean basin, such as Jews, Armenians,
Turks, and Arabs, is 1/200–1/1000 (1,2). The clinical
manifestations include recurrent, self-limiting episodes
of fever and painful polyserositis, particularly peritonitis,
pleuritis, and arthritis; nausea and vomiting; common
weakness; and chest and joint pain (3,4).
In the Diagnostic and Statistical Manual of Mental
Disorders 5 (DSM-5), female sexual dysfunction (FSD)
includes sexual interest/arousal disorder, orgasmic
disorder, genito-pelvic pain/penetration disorder,
substance/medication-induced sexual dysfunction, and
other specified and unspecified sexual dysfunctions (5). It
is a highly prevalent problem that is often underestimated
in the general population (6).
Another common clinical presentation in women
with FMF is premenstrual symptoms (7), which is defined
* Correspondence: dr_ugurlu@yahoo.com

as a set of affective, cognitive, and physical symptoms
during the premenstrual phase of the menstrual cycle
(8). The most common premenstrual symptoms are low
mood, tension, bouts of anger or irritability, mood swings,
headache, abdominal distention, and appetite and sleep
disturbances (9). Its prevalence has been reported as 3%–
8% (10,11).
Studies have shown that chronic rheumatic diseases
negatively affect female sexual function and premenstrual
symptoms (12,13). The drugs used in the treatment of
chronic rheumatic diseases, the pathogenesis of the
rheumatic disease, and disease-caused psychosocial
factors can trigger new cases of premenstrual symptoms
and FSD or aggravate existing cases (14,15). Female sexual
function has not been studied sufficiently in patients with
FMF, and there are few studies regarding the relationship
between FMF and premenstrual syndrome. As such, the
aim of this study was to investigate the effects of FMF and
depression/anxiety associated with FMF on female sexual
function and premenstrual symptoms.
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2. Materials and methods
This study was organized jointly by the Rheumatology
Department, outpatient clinics, and Psychiatry Department
of Ankara Atatürk Training and Research Hospital, a
tertiary care hospital. The protocol was approved by the
ethics committee of Yıldırım Beyazıt University (Ankara
Atatürk Training and Research Hospital is affiliated with
Yıldırım Beyazıt University, Faculty of Medicine) and
conducted in accordance with the Declaration of Helsinki
and the Guideline for Good Clinical Practice. Written
informed consent was obtained from the participants.
2.1. Participants and procedure
FMF was diagnosed according to the Tel Hashomer
criteria (16) in 36 female patients admitted to the Ankara
Atatürk Training and Research Hospital Rheumatology
Outpatient Department. Mediterranean fever mutations
were identified in all of the patients (Table 1). Other
research inclusion criteria were as follows: 18–50 years of
age, married or sexually active. The exclusion criteria of
the research were the presence of abdominal pain attack,
comorbid medical conditions, diagnosis of psychiatric
disorder in the previous 6 months, and regular use of
drugs or substances other than colchicine or contraception
medication. Thirty-three healthy volunteers matched for
age and education level (education levels were determined
according to the last schools from which they graduated)
were recruited using the same criteria.
Severity of depression and anxiety, which are considered
to have an impact on sexual function, and premenstrual
symptoms were determined by a scale. The severity of

premenstrual symptoms and sexual dysfunction were
evaluated by the same method. All scales were self-report
questionnaires and were introduced to the participants
before being filled out. The scales were applied in an
appropriate environment considering the privacy of the
participants and participants were given up to 30 min to
complete them. The theory about the relationship between
these measured variables and FMF was statistically tested.
2.2. Data collection instruments
2.2.1. Beck Depression Inventory (BDI)
This scale was developed by Beck in 1961 to determine
risk of depression and to assess the level and severity of
changes in depressive symptoms. A Turkish validity and
reliability study of the BDI was conducted in 1988 by Hisli.
The scale contains 21 items, and each item is assigned a
score of 0–3 based on four self-assessment options (17,18).
2.2.2. Beck Anxiety Inventory (BAI)
This scale, developed by Beck and colleagues, is a self-rating
scale used to determine the severity of anxiety symptoms.
This scale consists of 21 items and it is scored on a Likerttype scale of 0–3. A Turkish validity and reliability study of
the BAI was conducted in 1998 by Ulusoy et al. (19).
2.2.3. Premenstrual Assessment Form (PAF)
This 95-item self-report scale is used to measure emotional,
behavioral, and physical changes that might occur during
the premenstrual period. The PAF was developed by
Halbreich et al. (20), and a Turkish validity and reliability
study was conducted by Dereboy et al. (21). The PAF was
used to assess the severity of premenstrual symptoms.

Table 1. MEFV gene mutations in FMF patients.
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Mutations

N

%

M694V (homozygous)

10

27.8

M694V (heterozygous)

5

13.9

E148Q (homozygous)

8

22.2

E148Q (heterozygous)

2

5.6

M680I (heterozygous)

2

5.6

M694I (heterozygous)

2

5.6

M694V/V726A (compound heterozygous)

2

5.6

M694V/M680I (compound heterozygous)

1

2.8

M680I/R761H (compound heterozygous)

1

2.8

R202Q (heterozygous)

1

2.8

E148Q/P369S (compound heterozygous)

1

2.8

M694V/E148Q (compound heterozygous)

1

2.8
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2.2.4. Golombok Rust Inventory of Sexual Satisfaction
(GRISS) (women’s form)
This scale, developed by Rust and Golombok, provides
information regarding seven areas (frequency,
communication,
satisfaction,
avoidance,
touch,
vaginismus, and anorgasmia) of sexual function (22).
A Turkish validity and reliability study of the scale was
conducted by Tuğrul et al. (23).
2.3. Statistics
The statistical significance threshold was considered to
be P < 0.05. The distribution of variables was assessed by
the Shapiro–Wilks test and the Mann–Whitney U test was
used for comparisons. A model was created describing the
effects of FMF on anxiety, depression, PMS, and sexual
function. The significance of the model was examined by
path analysis. The effect size was calculated by considering
group means, assuming alpha of 0.05 and power of 0.80.
In the path analysis, we examined how sexual
function, anxiety, depression, and PMS are associated
with FMF. Path analysis can be used to describe the
effects of exogenous variables (group and depression)
on endogenous (vaginismus, frequency, anxiety, PMS)
variables directly, indirectly, and by the sum of these
variables. Path analysis enables an easy understanding of
these effects by visualization in a path diagram. Exogenous
variables in the model are those that are not explained
by any variable. Endogenous variables in the model are
those that are explained by exogenous variables or other
endogenous variables (anxiety was both endogenous
and exogenous in our study) (24,25). Path analysis can
predict that the equations system determines all causal
links in a variables system, solves complex relationships
between variables, and clearly reveals the strength of the
relationship (26). Suhr stated that if a path coefficient value
is smaller than 0.10, there is the presence of a weak effect;
if a path coefficient value is between 0.10 and 0.50, there is
the presence of a moderate effect; and if a path coefficient
value is greater than 0.50, there is the presence of a strong
effect (27).
3. Results
There were no statistically significant differences between
the groups in terms of age and educational level (age: MFMF
= 38.5, SDFMF = 6.9, MControls = 36.3, SDControls = 6.1, t(68)
= 1.405, P = 0.165; education: χ2 (2) = 0.648, P = 0.723).
All of the FMF patients in this study had been using
colchicine. The mean duration of colchicine use was 5.9
± 7.1 years. Thirteen of the patients with FMF (36.1%)
were using colchicine at 1 mg/day and 23 of the patients
with FMF (63.9%) were using colchicine at 1.5 mg/day.
We did not find a significant difference between patients
with FMF using colchicine at 1 mg/day and patients with
FMF using colchicine at 1.5 mg/day in terms of BAI,

BDI, PAF, and GRISS total and subscale scores. We found
statistical differences between groups in terms of BAI total
score, PAF total score, GRISS total score, and frequency
and vaginismus scores (subscales of GRISS). There were
no differences between groups in terms of BDI total score
or GRISS communication, satisfaction, touch, avoidance,
and anorgasmia subscale scores. Comparisons between
the total scale and subscale scores of the groups are
shown in Table 2. We used the 19th item of the BDI as an
indirect indicator of disease severity. When the 19th item
was compared between groups, there was no statistical
difference (MdnFMF = 0, MdnControls = 0, U = 490, P = 0.090).
A model was established that included statistically
significant variables between the two groups. The variables
included groups (FMF and healthy control groups), GRISS
frequency and vaginismus subscales, BDI, BAI, and PAF.
The Figure shows the described model. According to the
model, the group variable was found to have an effect on
the GRISS frequency and vaginismus subscale variables,
independent of anxiety and depression levels. In addition,
it had no direct effect on premenstrual syndrome, but it was
observed to have an effect on total PAF score (increased
level of anxiety). The group variable had no effect on
depression, but depression scores had a significant effect
on total PAF score. The values of the fitness of the model
are CMIN = 9.129; DF = 9; CMIN/DF = 1.014; P = 0.425;
GFI = 0.956; IFI = 0.999; CFI = 0.999; and RMSEA = 0.015.
4. Discussion
Our path model showed a perfect fit. One of the most
important results obtained from our study is that
FMF moderately increased the GRISS frequency and
vaginismus subscale scores. Previous studies have shown
that psychological factors caused by rheumatic disease
can cause sexual dysfunction (12). Similarly, other studies
have suggested that rheumatic diseases can directly (28) or
indirectly (29,30) cause physical effects on sexual function
(31). Although it has been reported that autonomic
neuropathy caused by amyloidosis may lead to impotence
in men (32), there is not enough information about the
direct effects of FMF on female sexual function in the
literature. According to our model, anxiety and depression
levels cannot explain the sexual dysfunction. Therefore,
another psychological factor is probably responsible.
It can be said that this psychological factor is anxiety
sensitivity. FMF is a disease characterized by episodes of
abdominal pain, which can adversely affect functionality
(33,34). Patients might avoid situations that cause this
pain (35), and patients with FMF may exhibit avoidance
or precautionary behaviors, believing that they can reduce
or stop pain in this way. Some studies have suggested that
exercise and emotional factors might increase episodes
of pain in patients with FMF (36). In addition, although
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Table 2. Comparison between groups in terms of anxiety, depression, sexual dysfunction, and premenstrual syndrome.

BAI
BDI
PAF
GRISS
Frequency
Communication
Satisfaction
Avoidance
Vaginismus
Anorgasmia
Touch

Groups

n

Median

PFMF

36

HC

IQR
25th

75th

19

10.5

29.0

33

7

1.5

13

PFMF

36

13.5

7.25

20.0

HC

33

10

5

14.5

PFMF

36

208.5

161.7

262.7

HC

33

154

127

201.5

PFMF

36

40.5

34.0

50.75

HC

33

36

22.5

47

PFMF

36

6

2

12

HC

33

4

1

5

PFMF

36

5.5

3

7

HC

33

4

3

6

PFMF

36

5

3

7

HC

33

4

2

7

PFMF

36

4.8

2

7

HC

33

4

2

7.5

PFMF

36

6.7

4

9

HC

33

5

4

7

PFMF

36

6

4

7.7

HC

33

5

2.5

7.5

PFMF

36

4.5

3

7

HC

33

4

2

6.5

Z

P

d

–4.418

<0.001

1.46

–1.732

0.083

0.37

–2.883

0.004

0.43

–2.019

0.043

0.73

–2.786

0.005

0.78

–1.126

0.260

0

–0.924

0.355

0.33

–0.459

0.646

0

–2.124

0.034

0.50

–0.966

0.334

0.33

–1.420

0.156

0.33

PFMF: Patients with familial Mediterranean fever, HC: healthy controls, BAI: Beck Anxiety Inventory, BDI: Beck Depression Inventory,
PAF: Premenstrual Assessment Form, GRISS: Golombok Rust Inventory of Sexual Satisfaction (women’s form), IQR: interquartile
range, d: Cohen’s d.

the probability of incidence decreases after colchicine
treatment (37), pelvic adhesions due to recurrent episodes
of abdominal serositis and exploratory laparoscopy (38)
can cause pain during sexual activity, or patients might
worry that FMF attacks might be triggered during sexual
activity. Therefore, patients might avoid sexual activity to
prevent pain attacks. This hypothesis may be a distinct
research topic.
The second important result of the model is that FMF
has no direct effect on PMS, but it indirectly increased the
total PAF score by increasing anxiety levels. The effects of
FMF on anxiety levels and the effects of anxiety on PMS
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are strong. It has been shown that estrogens can inhibit
interleukin 6 production and inhibition of this interleukin
may indirectly ameliorate the inflammatory process (39).
Thus, menstruation can trigger pain attacks in patients
with FMF (40). As such, the expectation of a pain attack
during menstruation might cause increased levels of
anxiety (41). Pain, including abdominal pain, is known to
elicit anxiety (42). Similar to our study, other studies have
shown strong positive correlations between anxiety and
PMS (43,44).
The reasons for the small sample size of this study are
that the research was planned as a single-center study, the
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Figure. Schematic representation of the effects of FMF on sexual and reproductive health in women.

inclusion criteria were strict, and both FMF patients and
healthy controls were reluctant to participate due to the
questions regarding sexual function. However, despite the
small sample size, for many variables, the effect size was
moderate or high (especially anxiety), and the difference
between groups was supported by path analysis. One of
the limitations of the study is that all of the FMF patients
were using colchicine, which might have caused sample
bias. However, colchicine (used in the treatment of FMF)
is generally well tolerated and there is no evidence of
sexual side effects (45), and no evidence was found in the
literature, using several screening databases (PubMed,
Science Direct, EBSCO), that colchicine has negative
effects on sexual function or PMS. Another limitation
of our study is the lack of a tool that directly measures
the severity of FMF (such as frequency of episodes of
abdominal pain). However, we tried to overcome this

problem by using the 19th item of the BDI. It measures the
perspective of the participants of their own health status
in the last week. We found that there was no significant
difference in perceived health between the two groups and
concluded that clinical measurements were performed
under ideal circumstances.
Improving the quality of life in patients with FMF is
as important as improving the symptoms associated with
FMF. With drugs such as colchicine, the symptoms of FMF
can be largely controlled, and long-term complications
associated with FMF have been greatly reduced. However,
psychiatric complications that adversely affect the quality
of sexual and reproductive life are still observed in FMF
patients. Therefore, it is extremely important that FMF
patients be evaluated for psychiatric comorbidities such as
sexual dysfunction and PMS.
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